Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Investor webinar

Tuesday, October 31, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has announced a series of updates, including the dosing of the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive clinical updates have been provided across four programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics is advancing its clinical studies.
  • The company has received IND approval from the US FDA.
  • Positive updates have been shared across multiple programs.

Full Press Release Details

• Announcements
• With Summary , With Video
• October 31, 2023
Announcement summary
Loading Viewer…

More Announcements & Updates

• Announcements
• May 23, 2024
• Announcements
• February 10, 2022
• Announcements
• July 16, 2024
• Announcements
• August 23, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What updates were shared in the investor webinar?

The webinar highlighted the dosing of the first patient in the Phase 1/2a study of BetaBart.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic candidate being studied by Radiopharm Theranostics.

Did Radiopharm receive any FDA approvals?

Yes, Radiopharm received IND approval from the US FDA for a clinical study targeting B7H3.

How many programs received positive updates?

Positive updates were provided across four different programs.

Tags: RADX Viatris Investor Conferences Healthcare BetaBart clinical study FDA approval radiopharmaceuticals
Last updated: Oct 31, 2023